Repligen | RGEN - Sales Revenues

Stock Price
116.61
Daily Change
-1.68 -1.42%
Monthly
4.59%
Yearly
-18.81%
Q2 Forecast
115.08

Repligen reported $197.91M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agilent USD 1.8B 63M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
Bio Techne USD 295.9M 9.34M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Bruker USD 977.2M 116.7M Dec/2025
Charles River Laboratories USD 994.2M 5.8M Dec/2025
Danaher USD 5.95B 890M Mar/2026
Dentsply International USD 961M 57M Dec/2025
General Electric Aerospace USD 11.6B 270M Mar/2026
Henry Schein USD 3.4B 60M Dec/2025
Illumina USD 1.16B 80M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Mettler Toledo International USD 1.13B 100M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Repligen USD 197.91M 8.91M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Standard Biotools USD 23.8M 4.24M Dec/2025
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Waters USD 932M 132M Dec/2025
West Pharmaceutical Services USD 844.9M 39.9M Mar/2026